Cover Image
市場調查報告書

生活方式OTC:趨勢、開發、機會及策略

Lifestyle OTCs: Trends, Developments, Opportunities and Strategies

出版商 Nicholas Hall & Company 商品編碼 314924
出版日期 內容資訊 英文
訂單完成後即時交付
價格
Back to Top
生活方式OTC:趨勢、開發、機會及策略 Lifestyle OTCs: Trends, Developments, Opportunities and Strategies
出版日期: 2014年12月04日 內容資訊: 英文
簡介

本報告提供肥胖治療、抽煙法規、止痛藥&睡眠補助藥、性的健康、眼睛保健品、家用診斷、全身性心血管疾病及降低膽固醇等,涵蓋各種類別的生活方式OTC的相關調查,促進眼睛保健品銷售額的主要趨勢,Statin OTC藥:Zocor的失敗後,非RX(非處方藥)有未來嗎,美國轉換到Lipitor會產生新的OTC類別嗎,睡眠輔助藥的ZzzQuil的華麗崛起的教訓,還有e-香煙的增加對傳統的OTC吸煙控制產品來說意味什麼的問題分析彙整,為您概述為以下內容。

摘要整理

眼睛保健品

  • 概要
  • 美國
    • 人工淚液
    • 眼科用去充血劑
    • 隱形眼鏡照護
    • 展望
  • 加拿大
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 波蘭
  • 中國
  • 日本
  • 澳洲
  • 印度
  • 韓國
  • 巴西
  • 墨西哥
  • 委內瑞拉
  • 眼睛保健品的展望

心臟的健康

  • 概要
  • 全身性心血管疾病
  • 膽固醇降低
  • 補充品
  • 心臟健康的展望

家用診斷

  • 概要
  • 血糖儀表
  • 血壓計
  • 家族計劃
  • 尿液檢查
  • 健身、睡眠監測

止痛藥&睡眠輔助藥

  • 概要
  • 美國
  • 加拿大
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 俄羅斯
  • 波蘭
  • 中國
  • 日本
  • 澳洲
  • 巴西
  • 墨西哥
  • 止痛藥&睡眠輔助藥的展望

性的健康

  • 概要
  • 避孕
  • 勃起障礙(ED)
  • 披衣菌感染治療

抽煙法規

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • Rx吸煙控制
  • OTC吸煙控制的展望

泌尿系統用醫藥品

  • 概要
  • UTI
  • 良性攝護腺肥大症(BPH)
  • 膀胱過動症(OAB)
  • 泌尿系統用醫藥品的展望

減重

  • 概要
  • 法規
  • 主要的全球發展
  • 美國的減重市場
  • 脂肪酶抑制劑

M生活方式OTC藥的展望

  • 全球生活方式OTC藥展望
  • 各分類的展望
目錄

Author: Nicholas Hall Reports

Publishing at the end of November is our new category report: Lifestyle OTCs. It will provide a comprehensive review of a vital part of the OTC industry covering such diverse categories as obesity treatments, smoking control, sedatives & sleep aids, sexual health, eye care, home diagnostics, systemic cardiovasculars and cholesterol reduction.

The report will help to answer a series of question including:

  • What are the key trends that will drive eye care sales?
  • Is there still a non-Rx future for statins after the failure of OTC Zocor? Can Lipitor switch in the US and create a successful new OTC category?
  • What can be learned from the meteoric rise of ZzzQuil among sleep aids?
  • What does the rise of e-cigarettes mean for traditional OTC smoking control products?

Chapters:

  • Executive Summary
  • Eye Care
  • Heart Health
  • Home Diagnostics
  • Sedatives & Sleep Aids
  • Sexual Health
  • Smoking Control
  • Urinary Products
  • Weight Loss
  • Lifestyle OTCs Outlook

Whether you already have a vested interest in this sector of the OTC market or are curious to find out the trends & opportunities and learn from existing strategies, Lifestyle OTCs will have something for you.

Table of Contents

Executive summary

Eye care

  • Overview
    • Does the rise of a handful of big-name eye health players foreshadow a consolidation of the category
    • Brands for older consumer - a largely unfulfilled niche?
  • USA
    • Artificial tears
    • Eye decongestants
    • Contact lens care
    • Looking ahead
  • Canada
    • Artificial tears
    • Eye decongestants
    • Contact lens care
  • France
    • Artificial tears
    • Eye decongestants
    • Eye washes
    • Blepharitis treatments
    • Homeopathics
  • Germany
    • Artificial tears
    • Eye decongestants
  • Italy
    • Eye decongestants
    • Other eye care segments
  • UK
    • Brand case study: Optrex
    • Other eye care brands
  • Spain
    • Pure OTC brands expand as semi-ethicals decline
  • Russia
    • Strongest growth driven by high adspend
    • Lower tier brands enjoy a wide range of positionings
  • Poland
    • Starazolin's meteroic rise to eye care No.1 a result of diversification and focused A+P
    • International brands compete for share in a fragmented lower tier
  • China
    • Strong performances across the category drive a healthy topline
  • Japan
    • New ingredient launches diversify allergy eye care market
    • Dynamism of longline Rohto range drives topline growth
    • NPD key to growth in the fragmented lower tier
  • Australia
    • Established brands drive topline growth
    • Lower tier sees significant NPD investment
  • India
  • South Korea
  • Brazil
  • Mexico
  • Venezuela
  • Outlook for eye care

Heart health

  • Overview
  • Systemic cardiovasculars
    • Will aspirin gain expanded indications?
    • C&E Europe
    • Western Europe
    • North America
    • Asia-Pacific
    • Latin America
  • Cholesterol reduction
    • Number of people taking Rx statins for cholesterol reduction is increasing at a fast pace
    • What is the potential for an OTC cholesterol reduction category based on statins?
    • Zocor Heart Pro - a switch failure in the UK
    • Lipitor to switch in the US?
  • Supplements for health health
    • Omega-3 for heart health boosted by positive studies...
    • ...However, doubts are raised over their benefits
    • Blockbuster Rx omega-3 supplement Lovaza has global
    • OTC potential
    • Krill oil-based omega-3 supplement MegaRed makes waves
    • Important omega-3 launch in Japan
    • Co-enzyme Q10 reputation grows thanks to studies
    • Do phytosterol supplements for cholesterol reduction have a future?
  • Outlook for heart health

Home diagnostics

  • Overview
  • Blood glucose meters
    • North America
    • Europe
    • Prospects for blood glucose meters
  • Blood pressure monitors
    • North America
  • Family planning
    • Ovulation tests
      • North America
      • Europe
      • Alternative ovulation tests
    • Fertility tests
    • Pregnancy tests
      • Innovation and technological advances in pregnancy tests
      • North America
      • Europe
    • STD tests
    • A lack of OTC options
    • Taking the shame out of STD testing
  • Urine tests
  • Fitness & sleep monitors

Sedatives & sleep aids

  • Overview
    • What are the chances of Rx insomnia treatments switching OTC?
  • USA
    • Rx insomnia segment offers potential switches
    • Brand case study: ZzzQuil
    • Natural sleep aids a significant segment
    • Nasal strips losing out to liquid brands and natural options
  • Canada
    • Nasal strip Breathe Right dominates the category
    • Competitive diphenhydramine segment invigorated by ZzzQuil
    • Naturals segment faces competition from longline VMS ranges
  • Germany
    • Baldriparan faces growing competition from dynamic Neurexan
  • France
    • Natural sleep aids are growing well, but could not offset continued decline of sedatives
  • Italy
    • Valdispert and Pineal take largest share of fragmented category
  • Spain
    • Dormidina secures its position at the head of a sluggish category
  • UK
  • Russia
    • Dynamism of Afobazol a key contributor to overall growth
  • Poland
  • China
    • Allopathic segment underdeveloped, with Rx options a barrier
    • TCMs continue to grow to challenge Nao Bai Jin
  • Japan
    • Despite efforts to improve consumer awareness, sales of leading brands remain low
  • Australia
    • Longline naturals ranges account for majority of sales
    • Marketers of medicated brands using alternative methods to promote non-advertisable OTCs
    • Wide range of medical devices compete within small anti-snoring segment
  • Brazil
    • Passiflora brands dominant in a generally dynamic category
    • Brand case study: Seakalm
  • Mexico
  • Outlook for sedatives & sleep aids

Sexual health

  • Overview
  • Contraception
    • Emergency hormonal contraception
      • Asia-Pacific
      • North America
      • Western Europe
      • EHC in other key markets
      • Prospects for EHC
    • Daily oral contraception
      • Asian markets provide bulk of (limited) OTC daily OC sales
      • Pilot schemes increase availability of DOC in the UK
      • Calls in the US to switch DOC
      • Prospects for daily Ocs
  • Erectile dysfunction
    • The OTC potential of ED
    • New Zealand makes "first in world" switch of sildenafil
    • Viagra's eventual switch seen by many as inevitable
    • Developments among the main ED brands
    • Sanofi and Eli Lilly plan Cialis OTC launch for 2018
    • Pharmacy availability of ED without a prescription in the UK
    • China's ED market sees generic Viagra launch
    • Marketing for ED skews towards humour ... and a younger demographic
    • Prospects for ED treatments
  • Chlamydia treatments
    • UK alone in offering OTC chlamydia treatment

Smoking control

  • Overview
  • North America
    • USA
    • Canada
  • Europe
    • UK
    • France
    • Nordic markets
    • Germany
    • Spain
    • Poland
    • Russia
  • Asia-Pacific
    • Australia
    • Japan
    • China
    • India
    • South Korea
  • Latin America
  • Rx smoking control
  • E-cigarettes
    • Overview
    • Impact on current smoking control market
    • Regulation of e-cigarettes
    • Future of e-cigarettes
  • Prospects for OTC smoking control

Urinary products

  • Overview
  • UTIs
    • Cystitis treatments on the up in Europe
    • Outside Europe, US is the key market for UTI treatments
    • Does switch of antibiotics for UTIs in New Zealand herald new era for OTC treatment?
  • Benign prostatic hyperplasia
    • OTC treatments for BPH currently limited
    • What impact has Flomax Relief's switch in the UK made?
  • Overactive bladder
  • Outlook for urinary products

Weight loss

  • Overview
  • Regulatory roundup
  • Key global developments
  • US weight loss market
    • US regulators working to ensure safety and reliability
    • Meal replacements and diet plans a significant segment of dietary aids
    • MLM a growing presence in the US dietary supplements category
    • Weight loss supplements
  • Lipase inhibitors
    • Xenical is present across certain Asian markets
    • Alli's strong launch gives way to disappointing sales period, but recovery is on the cards
    • Alli launch process a textbook example of advisory OTC launch
    • Marketing strategy emphasises Alli's USP

Lifestyle OTCs outlook

  • Global prospects for lifestyle OTCs
  • Category prospects
Back to Top